Alternatives to Exscientia

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Clinical-stage techbio company pairing automated wet labs with AI models to discover and develop drugs.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Physics-based molecular simulation with AI for drug discovery and materials design.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

AI drug discovery company pairing Enchant v3 and NeuralPLexer models with a weekly high-throughput wet lab and a wholly owned clinical pipeline.

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

BioStack Platforms supplies structured clinical datasets and RL environments for healthcare AI teams.

Silico is Goodfire's mechanistic interpretability agent for understanding, debugging, and steering the internals of your AI models.

Oncology real-world evidence built from point-of-care patient data, with AI-powered analysis layered on top.

All-in-human foundation models that read a routine blood draw to predict brain activity, therapy response, and side effects in neurology.

Iktos pairs generative AI for small-molecule design with AI retrosynthesis and robotic lab automation.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology on H&E slides, plus the Virchow and PRISM foundation models licensed to biopharma and researchers.

Quibim turns MRI, CT and PET scans into cleared, quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Cradle is an AI protein engineering platform that designs optimised variant plates from your own wet-lab results and feeds each round back into the models.

Cellino builds the manufacturing layer for personalized cell therapy: AI-guided optical bioprocessing on its modular Nebula™ platform.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Enterprise scientific intelligence platform whose Luma Agent plans, runs and documents R&D data analysis under human approval

Automated cloud lab for protein validation — binding, expression and thermostability assays with data back in as little as 3 days

WhiteLab Genomics' ALFRED platform predicts and optimizes molecular constructs for gene and RNA therapies before synthesis